SCHEMBL19950488

SCHEMBL19950488

Cc1cc(NC(=O)CCl)cc(F)c1-c1cc2c(-c3cnn(C)c3)nn(C(=O)O)c2cn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 9/20 0.44
NTRK1 P04629 4/20 0.44
KIT P10721 4/20 0.44
FLT3 P36888 4/20 0.44
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
S1PR2 O95136 2/20 0.35
ABL1 P00519 1/20 0.34
PIM1 P11309 2/20 0.33
MAPK1 P28482 1/20 0.33
AURKB Q96GD4 1/20 0.33
GSK3B P49841 2/20 0.33
DYRK1A Q13627 2/20 0.33
WNT1 P04628 1/20 0.33
STING1 Q86WV6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950315 0.95 ALDH1A1 (0.43) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19950429 0.92 ALDH1A1 (0.41) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19950076 0.91 ALDH1A1 (0.41) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19950599 0.90 MAP4K1 (0.46) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19949978 0.89 MAP4K1 (0.41) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL29746577 0.89 MAP4K1 (0.41) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19950714 0.88 MAP4K1 (0.38) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19950023 0.87 MAP4K1 (0.40) MAP4K1NTRK1KITFLT3ALDH1A1
SCHEMBL19950602 0.86 ALDH1A1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL19960726 0.84 MAP4K1 (0.40) MAP4K1NTRK1KITFLT3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.